PFE vs. PHG: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at PFE and PHG, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
PFE is a standard domestic stock, while PHG trades as New York Registered Shares, providing U.S. investors with a way to invest in the foreign-based company.
| Symbol | PFE | PHG |
|---|---|---|
| Company Name | Pfizer Inc. | Koninklijke Philips N.V. |
| Country | United States | Netherlands |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Pharmaceuticals | Health Care Equipment & Supplies |
| Market Capitalization | 144.30 billion USD | 26.43 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | June 1, 1972 | March 17, 1980 |
| Security Type | Common Stock | NY Reg Shrs |
Historical Performance
This chart compares the performance of PFE and PHG by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | PFE | PHG |
|---|---|---|
| 5-Day Price Return | 1.08% | 1.54% |
| 13-Week Price Return | 10.35% | 12.47% |
| 26-Week Price Return | -1.01% | -12.21% |
| 52-Week Price Return | -11.88% | -11.79% |
| Month-to-Date Return | 8.97% | 2.68% |
| Year-to-Date Return | -4.33% | -2.79% |
| 10-Day Avg. Volume | 36.18M | 1.10M |
| 3-Month Avg. Volume | 43.39M | 1.84M |
| 3-Month Volatility | 23.66% | 28.64% |
| Beta | 0.50 | 1.05 |
Profitability
Return on Equity (TTM)
PFE
11.96%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
PFE’s Return on Equity of 11.96% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.
PHG
-0.18%
Health Care Equipment & Supplies Industry
- Max
- 34.53%
- Q3
- 19.38%
- Median
- 9.52%
- Q1
- 4.86%
- Min
- -7.58%
PHG has a negative Return on Equity of -0.18%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
PFE
16.85%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
PFE’s Net Profit Margin of 16.85% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.
PHG
0.90%
Health Care Equipment & Supplies Industry
- Max
- 23.34%
- Q3
- 13.06%
- Median
- 9.53%
- Q1
- 5.96%
- Min
- -3.87%
Falling into the lower quartile for the Health Care Equipment & Supplies industry, PHG’s Net Profit Margin of 0.90% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.
Operating Profit Margin (TTM)
PFE
18.62%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
PFE’s Operating Profit Margin of 18.62% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
PHG
6.11%
Health Care Equipment & Supplies Industry
- Max
- 29.44%
- Q3
- 17.80%
- Median
- 13.95%
- Q1
- 8.73%
- Min
- -3.56%
PHG’s Operating Profit Margin of 6.11% is in the lower quartile for the Health Care Equipment & Supplies industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.
Profitability at a Glance
| Symbol | PFE | PHG |
|---|---|---|
| Return on Equity (TTM) | 11.96% | -0.18% |
| Return on Assets (TTM) | 5.08% | -0.08% |
| Net Profit Margin (TTM) | 16.85% | 0.90% |
| Operating Profit Margin (TTM) | 18.62% | 6.11% |
| Gross Profit Margin (TTM) | 73.96% | 43.85% |
Financial Strength
Current Ratio (MRQ)
PFE
1.16
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
PFE’s Current Ratio of 1.16 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
PHG
1.26
Health Care Equipment & Supplies Industry
- Max
- 4.90
- Q3
- 3.05
- Median
- 2.14
- Q1
- 1.49
- Min
- 0.86
PHG’s Current Ratio of 1.26 falls into the lower quartile for the Health Care Equipment & Supplies industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
PFE
0.70
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
PFE’s Debt-to-Equity Ratio of 0.70 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
PHG
0.81
Health Care Equipment & Supplies Industry
- Max
- 1.49
- Q3
- 0.71
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
PHG’s leverage is in the upper quartile of the Health Care Equipment & Supplies industry, with a Debt-to-Equity Ratio of 0.81. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
PFE
7.89
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
PFE’s Interest Coverage Ratio of 7.89 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
PHG
1.41
Health Care Equipment & Supplies Industry
- Max
- 58.29
- Q3
- 25.56
- Median
- 9.06
- Q1
- 3.60
- Min
- -28.92
In the lower quartile for the Health Care Equipment & Supplies industry, PHG’s Interest Coverage Ratio of 1.41 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.
Financial Strength at a Glance
| Symbol | PFE | PHG |
|---|---|---|
| Current Ratio (MRQ) | 1.16 | 1.26 |
| Quick Ratio (MRQ) | 0.85 | 0.81 |
| Debt-to-Equity Ratio (MRQ) | 0.70 | 0.81 |
| Interest Coverage Ratio (TTM) | 7.89 | 1.41 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
PFE
6.65%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
With a Dividend Yield of 6.65%, PFE offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
PHG
0.00%
Health Care Equipment & Supplies Industry
- Max
- 4.05%
- Q3
- 1.76%
- Median
- 0.71%
- Q1
- 0.00%
- Min
- 0.00%
PHG’s Dividend Yield of 0.00% is consistent with its peers in the Health Care Equipment & Supplies industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
PFE
89.67%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
PFE’s Dividend Payout Ratio of 89.67% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
PHG
0.42%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 72.47%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
PHG’s Dividend Payout Ratio of 0.42% is within the typical range for the Health Care Equipment & Supplies industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | PFE | PHG |
|---|---|---|
| Dividend Yield (TTM) | 6.65% | 0.00% |
| Dividend Payout Ratio (TTM) | 89.67% | 0.42% |
Valuation
Price-to-Earnings Ratio (TTM)
PFE
13.48
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
In the lower quartile for the Pharmaceuticals industry, PFE’s P/E Ratio of 13.48 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
PHG
140.05
Health Care Equipment & Supplies Industry
- Max
- 73.48
- Q3
- 51.69
- Median
- 34.31
- Q1
- 25.74
- Min
- 11.47
At 140.05, PHG’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Health Care Equipment & Supplies industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
Price-to-Sales Ratio (TTM)
PFE
2.27
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
PFE’s P/S Ratio of 2.27 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
PHG
1.26
Health Care Equipment & Supplies Industry
- Max
- 9.53
- Q3
- 5.26
- Median
- 3.39
- Q1
- 2.13
- Min
- 0.00
In the lower quartile for the Health Care Equipment & Supplies industry, PHG’s P/S Ratio of 1.26 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
PFE
1.55
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
PFE’s P/B Ratio of 1.55 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
PHG
1.89
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 5.98
- Median
- 3.48
- Q1
- 2.43
- Min
- 0.69
PHG’s P/B Ratio of 1.89 is in the lower quartile for the Health Care Equipment & Supplies industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | PFE | PHG |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 13.48 | 140.05 |
| Price-to-Sales Ratio (TTM) | 2.27 | 1.26 |
| Price-to-Book Ratio (MRQ) | 1.55 | 1.89 |
| Price-to-Free Cash Flow Ratio (TTM) | 10.63 | 14.66 |